此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

症状出现后4.5-24小时内急性缺血性卒中患者的单次推注非免疫原性葡激酶 (FRIDA-CT)

2026年11月10日 更新者:Supergene, LLC

症状发作后4.5-24小时内急性缺血性卒中患者中重组非免疫性葡激酶疗效和安全性的多中心、双盲、随机、安慰剂对照研究(FRIDA-CT)

Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.

研究概览

详细说明

The current guidelines recommended intravenous thrombolysis as the first-line treatment for acute large vessel occlusion of anterior circulation stroke within 4.5 hours of stroke onset. However, a majority of patients arrive in the hospital outside the 4.5-hour time window, who could not receive intravenous thrombolysis.

In 2020, the non-immunogenic staphylokinase was registered in Russia for the acute ischemic stroke treatment within 4,5 h after the onset of symptoms. In the FRIDA randomized clinical trial the non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus of 10 mg regardless patients' bodyweight, simplifying clinical use. In 2024, the non-immunogenic staphylokinase has been included in the updated Russian clinical guidelines for the acute ischemic stroke treatment.

A rapid (10 s) single bolus of the non-immunogenic staphylokinase in patients with acute ischemic stroke may provide significant advantages over a one-hour alteplase administration in the more rapid reperfusion in the first 24 hours after thrombolysis and a greater number of good functional outcomes. It can be assumed that the non-immunogenic staphylokinase usage in patients with acute ischemic stroke outside the 4.5-hour therapeutic window will lead to the restoration of collateral blood flow in the penumbra in comparison with standard medical management.

Therefore, FRIDA-CT trial is aimed to investigate the efficacy and safety of the non-immunogenic staphylokinase within the time window of 4.5-24 hours, wake-up stroke or no witness stroke in patients who had an acute ischaemic stroke with salvageable tissue due to large vessel occlusion.

In the multicenter, double-blind, randomized, placebo-controlled phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume <70 mL, mismatch ratio ≥1.8 and mismatch volume ≥15 mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) will be included and randomised to the non-immunogenic staphylokinase, 10 mg (single bolus) regardless patient's bodyweight or placebo group. Patients who are intended for direct thrombectomy will be excluded from the trial. Follow-up period will be 90 days.

研究类型

介入性

注册 (估计的)

1050

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Nikolay A. Shamalov, MD, prof
  • 电话号码:+7 (499) 936-99-37
  • 邮箱:shamalovn@gmail.com

研究联系人备份

学习地点

      • Chelyabinsk、俄罗斯
        • 招聘中
        • Chelyabinsk Regional Clinical Hospital No. 3
        • 接触:
        • 首席研究员:
          • Dmitry V. Popov, PhD
      • Irkutsk、俄罗斯、664079
        • 招聘中
        • Irkutsk Regional Clinical Hospital
        • 接触:
        • 首席研究员:
          • Ivan V. Korobeynikov, PhD
      • Kazan'、俄罗斯、420101
        • 招聘中
        • Interregional Clinical and Diagnostic Center
        • 接触:
        • 首席研究员:
          • Dina R. Khasanova, MD, Prof
      • Krasnodar、俄罗斯、350086
        • 招聘中
        • S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1
        • 接触:
        • 首席研究员:
          • Ludmila V. Timchenko, MD, prof
      • Krasnogorsk、俄罗斯、143408
        • 招聘中
        • Krasnogorsk Clinical Hospital
        • 接触:
          • Svetlana V. Alexandrova
          • 电话号码:+7 (498) 602-03-73
          • 邮箱:clairalex@mail.ru
        • 首席研究员:
          • Svetlana V. Alexandrova
      • Moscow、俄罗斯、108814
        • 招聘中
        • Moscow Multidisciplinary Clinical Center "Kommunarka"
        • 接触:
        • 首席研究员:
          • Denis N. Protsenko, PhD
      • Moscow、俄罗斯、117997
        • 招聘中
        • N.I. Pirogov Russian National Research Medical University
        • 接触:
        • 首席研究员:
          • Larisa L. Korsunskaya, MD, Prof
      • Nizhny Novgorod、俄罗斯、603126
        • 尚未招聘
        • N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
        • 接触:
        • 首席研究员:
          • Valentina N. Nesterova, PhD
      • Orenburg、俄罗斯
        • 招聘中
        • V.I. Voynov Orenburg Regional Clinical Hospital
        • 接触:
        • 首席研究员:
          • Alexandr N. Chirkov, PhD
      • Saint Petersburg、俄罗斯、193079
        • 招聘中
        • St. Petersburg Hospital for War Veterans
        • 接触:
        • 首席研究员:
          • Maria A. Privalova, PhD
      • Saint Petersburg、俄罗斯、194291
        • 招聘中
        • Leningradskaya Regional Clinical Hospital
        • 接触:
        • 首席研究员:
          • Natalya V. Zhukovskaya, MD, prof
      • Solnechnogorsk、俄罗斯、141508
        • 尚未招聘
        • Solnechnogorsk District Hospital
        • 首席研究员:
          • Anton G. Koledinsky, MD, PhD
        • 接触:
          • Anton G. Koledinsky, MD, PhD
          • 电话号码:+7 (496) 264-14-56
          • 邮箱:koledant@mail.ru
      • Tver'、俄罗斯、170036
        • 招聘中
        • Tver Regional Clinical Hospital
        • 接触:
          • Ksenia V. Khoroshavina
          • 电话号码:+7 (482) 277-54-65
          • 邮箱:kseniarep@mail.ru
        • 首席研究员:
          • Ksenia V. Khoroshavina
      • Ulyanovsk、俄罗斯
        • 招聘中
        • Ulyanovsk Regional Clinical Hospital
        • 接触:
        • 首席研究员:
          • Irina V. Greshnova, PhD
      • Volgograd、俄罗斯、400138
        • 招聘中
        • City Clinical Hospital of Emergency Medical Care No. 25
        • 接触:
        • 首席研究员:
          • Eduard A. Ponomarev, MD, prof
      • Yekaterinburg、俄罗斯、620102
        • 招聘中
        • Sverdlovsk Regional Clinical Hospital No. 1
        • 接触:
        • 首席研究员:
          • Andrey M. Alasheev, MD, prof
    • Ryazan Oblast
      • Ryazan、Ryazan Oblast、俄罗斯、390039
        • 尚未招聘
        • Ryazan Regional Clinical Hospital
        • 接触:
        • 首席研究员:
          • Sergei B. Aksentyev, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Men and women aged 18 years and over;
  2. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
  3. Pre-stroke modified Rankin scale (mRS) score≤1;
  4. Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;
  5. Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume <70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;
  6. Alberta Stroke Program Early CT score (ASPECTS) > 6;
  7. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);
  8. The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;
  9. Written informed consent from patients or their legally authorized representatives.

Exclusion Criteria:

  1. Acute ischemic stroke within 4,5 h after symptom onset;
  2. Intended to proceed to endovascular treatment;
  3. Known hypersensitivity to the non-immunogenic staphylokinase;
  4. Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;
  5. Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;
  6. Blood glucose <2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);
  7. Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;
  8. Subarachnoid hemorrhage;
  9. Major bleeding currently or within the past 6 months;
  10. Surgery on the brain or spinal cord in the last 2 months;
  11. Punctures of non-compressible arteries and veins in the last 7 days;
  12. Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;
  13. Platelet count below 100,000/mm3;
  14. Previous stroke or severe traumatic brain injury within 3 months;
  15. Unable to perform CT or MRI;
  16. History of hemorrhagic stroke or stroke of unspecified genesis;
  17. Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
  18. Concomitant use of indirect oral anticoagulants (warfarin) with INR > 1.7;
  19. Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;
  20. Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).
  21. Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;
  22. Acute pancreatitis;
  23. Bacterial endocarditis, pericarditis;
  24. Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;
  25. Cancer with an increased risk of bleeding;
  26. Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;
  27. Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);
  28. Hemorrhagic diathesis, including renal and hepatic failure;
  29. Data on bleeding or acute trauma (fracture) at the time of examination;
  30. Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Placebo

Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization

实验性的:Non-immunogenic staphylokinase

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

其他名称:
  • Fortelyzin®

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Excellent functional outcome
大体时间:90 days

The number of patients with excellent functional outcome defined as an mRS score 0-1 at 90 days

90 days

次要结果测量

结果测量
措施说明
大体时间
Ordinal distribution of mRS
大体时间:90 days

Ordinal distribution of mRS at 90 days

90 days
Functional independence outcome
大体时间:90 days

The number of patients with functional independence defined by an mRS score 0-2 point at 90 days

90 days
NIHSS change from baseline
大体时间:7-14 days

NIHSS median change from baseline on discharge

7-14 days
The rate of improvement on reperfusion
大体时间:24 hours

The number of patients with recanalization of 2 and 3 points on the arterial occlusion scale (rAOL) 24 hours after drug administration according to CT (MRI) angiography, where 0 points - complete occlusion, 3 points - complete recanalization.

24 hours
All-cause mortality
大体时间:90 days

Rate of all-cause mortality within 90 days

90 days
Poor functional outcome
大体时间:90 days

The number of patients with poor functional outcome defined by an mRS score 5-6 point at 90 days

90 days

其他结果措施

结果测量
措施说明
大体时间
Hemorrhagic transformation
大体时间:24 hours

Rate of hemorrhagic transformation according to The Heidelberg Bleeding Classification within 24 hours

24 hours
Symptomatic intracranial hemorrhage
大体时间:24 hours

Rate of symptomatic intracranial hemorrhage (sICH) (as defined by The European Cooperative Acute Stroke Study III criteria [ECASSIII] and Safe Implementation of Thrombolysis in Stroke-Monitoring Study [SITS-MOST]) within 24 hours

24 hours
Major bleeding
大体时间:90 days

Rate of major bleeding at 90 days (as defined by the Bleeding Academic Research Consortium (BARC) scale: type 3 and type 5)

90 days
Serious adverse events (SAEs)
大体时间:90 days

Rate of serious adverse events (SAEs) within 90 days

90 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nikolay A. Shamalov, MD, prof、Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
  • 研究主任:Sergey S. Markin, MD, prof、LLC "SuperGene"

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月9日

初级完成 (估计的)

2028年11月1日

研究完成 (估计的)

2029年1月1日

研究注册日期

首次提交

2025年12月23日

首先提交符合 QC 标准的

2025年12月23日

首次发布 (实际的)

2026年1月8日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The funder of the study is committed to the responsible sharing of data from FRIDA-CT trail. Data will be provided to any qualified investigator on reasonable request. Deidentified participant data will be available after the publication of the results of the completed study on request to the corresponding author.

IPD 共享时间框架

within 90 days after request

IPD 共享访问标准

Proposals will be reviewed and approved by the funder and Data and Safety Monitoring Board. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅